Table 1.
Efficacy and safety of combination treatment with PRRT.
| Combination Partner | ORR (%) | OS (Month) |
PFS (Month) |
SAE (%) | Ref |
|---|---|---|---|---|---|
| Dual PRRT Lu-177 and Y-90 | 42 | 66–127 | - | 2% MDS, 2% nephrotoxicity, 7% hematotoxicity |
[20,32,33,34,35,36,37] |
| Capecitabine | 24–30 | not reached | 31 | <15% anemia/thrombocytopenia/neutropenia 5% fatigue/diarrhea |
[38,39,40] |
| CAPTEM | 53–70 | not reached | 22–48 | 6% neutropenia, 3% nausea | [41,42,43] |
| 5-fluorouracil | 25 | not reached | - | - | [44] |
| SSA | 37 | 91 | 48 | 3% hepatotoxicity | [45,46] |
| EBRT | 0 | not reached | 108 | 0% | [47] |
| Liver embolization | 16 (Y-90) 43 (Ho-166) |
42–68 | - | 10% abdominal pain, 3% fatigue/nausea, >20% lymphocytopenia, 5% radiation-induced gastric ulceration, 2% radiation pneumonitis, 2% liver abscess, 2% cholangitis, 50% liver enzyme elevation, <5% liver failure (2–3% fatal) |
[48,49,50] |
| Everolimus | 44 | not reached | not reached (63% at 24 months) | mainly hematotoxicity (thrombocytopenia, anemia) in the 10 mg/d everolimus dose group 100%, one case (6%) hepatotoxicity | [51] |
| [131I]I-MIBG | 0 | - | - | one case of three (33%) thrombocytopenia | [52] |
ORR = objective response rate; OS = overall survival; PFS = progression-free survival; SAE = serious adverse events according to CTCAE; Cave! In the table are listed collective SAE from different references. These SAE correlate only with the studied cohort in the particular investigation; Ref = references; MDS = myelodysplastic syndrome; CAPTEM = capecitabine and temozolomide; SSA = somatostatin receptor analogues; [131I]I-MIBG = [131I]I-metaiodobenzylguanidine; EBRT = fractionated external beam radiotherapy.